Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,439 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,439 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01463410 | Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the… | — | terminated | Nov 1, 2011 | Skyline Diagnostics BV | The required number of banked samples could not be met due to limited availability. There is no… | Other (stated, no rule matched) |
| NCT01251809 | Trial of Oncaspar® and Three Doses of Pegylated Recombinant Asparaginase in Adult… | Phase 1 / Phase 2 | terminated | Dec 2, 2010 | medac GmbH | not stated | Not stated |
| NCT00124644 | Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute… | Phase 1 | terminated | Jul 28, 2005 | Ohio State University Comprehensive Cancer Center | Withdrawn due to "toxicity" problems | Safety / toxicity |
| NCT00066417 | Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia | Phase 2 | terminated | Aug 7, 2003 | National Heart, Lung, and Blood Institute (NHLBI) | Trial was withdrawn for drug availability issues. | Drug supply |
| NCT00393380 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an… | Phase 2 | terminated | Oct 27, 2006 | The Emmes Company, LLC | Study stopped because of toxicity concerns. | Safety / toxicity |
| NCT00899951 | Studying Fentanyl in Patients With Cancer | — | terminated | May 12, 2009 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | poor accrual | Enrollment / accrual |
| NCT00968461 | Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders | Phase 1 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00658411 | Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation | N/A | terminated | Apr 15, 2008 | Dana-Farber Cancer Institute | Closed due to slow patient accrual | Enrollment / accrual |
| NCT01508260 | Ultrafiltration (Aquapheresis) in Patients With Leukemia and Severe Fluid Overload | N/A | withdrawn | Jan 11, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00499668 | Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients… | N/A | withdrawn | Jul 11, 2007 | Vanderbilt-Ingram Cancer Center | slow accrual | Enrollment / accrual |
| NCT00601991 | A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia | Phase 2 | withdrawn | Jan 28, 2008 | Vanderbilt-Ingram Cancer Center | Another study was opened. | Other (stated, no rule matched) |
| NCT00030355 | Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia | Phase 1 / Phase 2 | withdrawn | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00087009 | Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive… | Phase 1 | terminated | Jul 12, 2004 | Memorial Sloan Kettering Cancer Center | Lack of Accrual | Enrollment / accrual |
| NCT00003435 | Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood… | Phase 1 | withdrawn | Jun 9, 2004 | Duke University | not stated | Not stated |
| NCT01101412 | Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2010 | M.D. Anderson Cancer Center | Study was not opened. | Other (stated, no rule matched) |
| NCT00006220 | Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer… | Phase 1 / Phase 2 | terminated | May 20, 2004 | Washington University School of Medicine | Study drug became commercially available. | Other (stated, no rule matched) |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00086840 | CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Phase 2 | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00089388 | Cilengitide in Treating Patients With Acute Myeloid Leukemia | Phase 2 | terminated | Aug 5, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00096148 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly… | Phase 2 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00023920 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic… | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00042796 | Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01265199 | Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of… | Phase 1 | terminated | Dec 23, 2010 | Ascenta Therapeutics | Study was terminated before a MTD was determined for administrative reasons | Other (stated, no rule matched) |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01148134 | Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive… | — | terminated | Jun 22, 2010 | University Health Network, Toronto | Analysis of the first 10 patients did not show anyt trend toward differences in PK profiles between… | Other (stated, no rule matched) |
| NCT00100971 | Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Jan 10, 2005 | Boston Medical Center | Protocol is withdrawn due to inadequate accrual | Enrollment / accrual |
| NCT00125606 | Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With… | Phase 3 | terminated | Aug 1, 2005 | University Hospital Muenster | insufficient patient recruitement | Enrollment / accrual |
| NCT00005641 | Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone… | Phase 2 | terminated | Jun 8, 2004 | H. Lee Moffitt Cancer Center and Research Institute | low study accrual | Enrollment / accrual |
| NCT00005852 | Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection… | Phase 2 | terminated | Jul 26, 2004 | H. Lee Moffitt Cancer Center and Research Institute | low accrual | Enrollment / accrual |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | M.D. Anderson Cancer Center | Lack of Response | Other (stated, no rule matched) |
| NCT00636155 | EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | terminated | Mar 14, 2008 | David Rizzieri | funding | Funding |
| NCT00002761 | Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating… | Phase 1 / Phase 2 | withdrawn | Nov 24, 2003 | Columbia University | PI left institution | Investigator |
| NCT01649622 | Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL) | Phase 2 | withdrawn | Jul 25, 2012 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00972101 | Infusion of Expanded Cord Blood T Cells | Phase 1 | withdrawn | Sep 4, 2009 | M.D. Anderson Cancer Center | Development of other studies led to termination without recruitment. | Enrollment / accrual |
| NCT00006090 | Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic… | Phase 2 | withdrawn | Mar 25, 2004 | M.D. Anderson Cancer Center | No enrollment. | Enrollment / accrual |
| NCT00069992 | Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in…(MPDMDSBMT) | Phase 2 | terminated | Oct 7, 2003 | Baylor College of Medicine | Closed due to competing protocols | Other (stated, no rule matched) |
| NCT00991744 | Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute… | Phase 3 | suspended | Oct 8, 2009 | Nordic Society for Pediatric Hematology and Oncology | Sterility problems in DepoCyte production | Other (stated, no rule matched) |
| NCT00301912 | Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With… | Phase 2 | withdrawn | Mar 13, 2006 | University of California, San Francisco | Withdrawn because study never opened to accrual | Enrollment / accrual |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is… | Phase 1 | terminated | Apr 15, 2005 | Novartis Pharmaceuticals | Slow enrollment and minimal preliminary biological and clinical efficacy. | Efficacy / futility |
| NCT00006092 | Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | Phase 2 | terminated | Jan 27, 2003 | H. Lee Moffitt Cancer Center and Research Institute | low accrual | Enrollment / accrual |
| NCT00003729 | Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute… | Phase 2 | terminated | Dec 10, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00062231 | Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in… | N/A | terminated | Jun 6, 2003 | European Organisation for Research and Treatment of Cancer - EORTC | low accrual | Enrollment / accrual |
| NCT00676728 | A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or… | Phase 1 | terminated | May 13, 2008 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Sponsor Decision | Sponsor / business decision |
| NCT00058747 | AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™ | Phase 2 | terminated | Apr 15, 2003 | Agenus Inc. | Business decision of the sponsor | Sponsor / business decision |
| NCT01659047 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single… | Phase 2 | withdrawn | Aug 7, 2012 | Gilead Sciences | not stated | Not stated |
| NCT00038818 | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell… | N/A | terminated | Jun 7, 2002 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00113321 | Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure | Phase 2 | terminated | Jun 8, 2005 | M.D. Anderson Cancer Center | Low Accrual | Enrollment / accrual |
| NCT00453193 | Alemtuzumab and Pentostatin In T-cell Neoplasms | Phase 2 | terminated | Mar 28, 2007 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 4, 2013source: clinicaltrials